All In Biotech

Drug Trial Radar · NCT04072640

Three Induction Treatments on Cryptococcal Meningitis

The Effect and Safety of Three Initial Introduction Treatments on HIV-infected Patients With Cryptococcal Meningitis: A Multi-center, Random and Prospective Study

Last checked: Nov 20, 2026Latest source record: Feb 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Jan 25, 2021

Primary completion

Jul 31, 2022

Study completion Dec 1, 2022

Sponsor

Lead sponsor
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Wenzhou Central Hospital
First posted
Aug 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Three induction treatment strategies \[ voriconazole +5FC vs. amphotericin deoxycholate (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC \] for HIV-infected patients with cryptococcal meningitis were compared.

Conditions

  • Cryptococcal Meningitis
  • HIV/AIDS

Interventions

  • Voriconazole 200mgDrug

    Induction treatment with voriconazole( 400mg/d)+5FC (100mg/kg/d) for 14 days;

  • amphotericin B deoxycholate (0.4-0.5mg/kg/d)Drug

    Induction treatment with 0.4-0.5mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 28 days

  • Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)Drug

    Induction treatment with 0.7-1.0mg/kg/d of Amphotericin B-deoxycholate +5FC(100mg/kg/d) for 14 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 90-day Cryptococcal Meningitis (CM) related mortalityTime frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lijun Xu

    Zhenjiang, Hangzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.